OpenAlex
PricingAboutJobs
Log inGet started
Work

Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-arm, phase II study.

HTML

Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2026.44.16_suppl.4110
Authors: Yiming Zhao, Longrong Wang, Anrong Mao, Weiping Zhu, Ti Zhang, Qi Pan, Lu Wang
Institution: Fudan University Shanghai Cancer Center
Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: tislelizumab, donafenib, GEMOX, gemcitabine, oxaliplatin, advanced biliary tract cancer, cholangiocarcinoma, gallbladder cancer, first-line therapy, immune checkpoint inhibitors, combination chemotherapy, objective response rate, progression-free survival, treatment safety, PD-1/PD-L1 blockade, tyrosine kinase inhibitors
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W7162575554
Cites:
Cited by:
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security